The OVATION-2 Study is evaluating GEN-1 (IMNN-001), an investigational* immunotherapy designed to use the body’s own immune system, combined with the standard of care treatment, to help fight ovarian cancer cells.
When cancer cells develop, the body’s disease-fighting immune system may not detect or be able to attack the cancer. Immunotherapy is any type of therapy that impacts the body’s immune system. In cancer treatment, immunotherapy is designed to help the body recognize and attack to destroy cancer cells.
Why is immunotherapy so promising for cancer treatment?
If safe and effective, immunotherapy may potentially provide a way for the immune system to continuously recognize and attack cancer cells while leaving healthy cells unaffected.
GEN-1 (IMNN-001), the investigational immunotherapy being evaluated in the OVATION-2 Study, consists of a DNA molecule that contains a gene encoded for a protein known as IL-12, which stimulates immune cells to recognize cancer cells and attack to destroy them, potentially aiding standard cancer treatment. This therapy is administered directly to the location of the cancer (in this case, into the abdomen), where cells can be activated to produce IL-12.
HOW IS GEN-1 (IMNN-001) ADMINISTERED?
GEN-1 (IMNN-001) is administered through a port and catheter that is inserted directly into the abdomen. The infusion takes between 1-2 hours and is administered weekly. This port will be placed in participants receiving GEN-1 (IMNN-001) during a surgical procedure while under general anesthesia.
*Investigational — Not yet approved for use by the FDA